A POST-APPROVAL, OBSERVATIONAL STUDY TO ASSESS CLINICAL IMPACT OF GLYCOPYRRONIUM IN HIGH RISK COPD WITH FREQUENT EXACERBATIONS: POST HOC ANALYSES

  • Sr. Consultant Pulmonologist, Jaypee Hospitals, Sector 128, Noida, India - 201304.
  • Sr. Consultant Chest Physician, Saifee Hospital, Department of Respiratory and Chest Medicine, Maharshi Karve Marg, Mumbai, India - 400004
  • General Manager, Medical Services, Glenmark Pharmaceuticals Ltd, Mumbai, India - 400099.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • How to Cite This Article
  • Corresponding Author

Background: Exacerbations remain a distinct clinical challenge in Chronic obstructive pulmonary disease (COPD) with consequent use of ICS in real-world practice of India. LAMA add-on therapy has been well highlighted by UPLIFT, TRIBUTE & KRONOS studies. Glycopyrronium add on therapy offers quick control of morning symptoms for likely improved patient adherence rates in COPD Objectives: To assess the clinical impact and use of Glycopyrronium add-on therapy in outpatient settings, real world observational study was planned. Methods and Material: National, post-approval, observational, drug utilization, concurrent analyses was carried out at 128 centers during Sept ’17 with institutional Ethics & CTRI registration. Post-hoc analyses was carried out by Quick Calcs GraphPad Prism ver. 7 software with p<0.05 considered as statistically significant Results: The per protocol analyses for 1117 consecutive Glycpyrronium & ICS/LABA combination cases was conducted for patients with baseline demographics included Male/Female (76%/24%); mean Age 59.5y; FEV1 (1.46 L/min, 48.9±16%), FEV1/FVC (58.7±13.3%); Reversibility (13.7±16.2%), Exacerbation (?1/y; 1117, 100%; ?2/y, 389,35%), CAT (22±10). At 12 weeks, the overall group (1117) and frequent exacerbators (389) showed prebronchodilator FEV1& CAT score change of 21% && 5.1 respectively (p<0.0001) at 12 wks. Post-hoc analyses for frequent exacerbators’ (?2/y, BDR ?10%, n=152) showed clinically significant change in prebronchodilator FEV1& CAT score of 22.8% & 5.4 respectively (p<0.0001) respectively showing positive test of interaction. Similarly the prebronchodilator FEV1 improvement for Frequent exacerbators’ with Reversibility (?2/y, BDR ?12%, n=156) was documented as 35% (p<0.0001). TEAEs included dry mouth (42, 3.8%), constipation (4,0.4%), exacerbation (2,0.2%) that were managed with symptomatic therapy

  1. Barrecheguren M, Esquinas C, Miravitlles M (2015). The asthma?chronic obstructive pulmonary disease overlap syndrome (ACO): opportunities and challenges. CurrOpinPulm Med., 21:74?79.
  2. Dandona L (2018). India State-Level Disease Burden Initiative CRD Collaborators*. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990?2016. Lancet Glob Health., 6: e1363?74
  3. Deb A, Agarwal M, Reddy V, Kodgule R, Hemalatha VS, Awasthi AK, et al (2016). Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD. EurResp Jour., 48: PA654. Available from: https://erj.ersjournals.com/content/48/suppl_60/PA654. [Accessed on July-20-2019]
  4. GINA updated (2019).Global initiative on Bronchial asthma. A Pocket Guide for Health Professionals. Available from: https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/pdf. [Accessed on July-29-2019]
  5. GOLD report (2019). Global initiative on Chronic obstructive lung disease. Pocket Guide To COPD Diagnosis, Management, And Prevention. A Guide for Health Care Professionals. Available from : https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. [Accessed on July-28-2019]
  6. Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpel?inen M, Kinnula VL, et al (2011). Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma., 48:279?285.
  7. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, IMPACT Investigators (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med., 378(18):1671-1680
  8. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al (2018). Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet., 391(10125):1076-10784.
  9. Plaza V, ?lvarez F, Calle M, Casanova C, Cos?o BG, L?pez-Vi?a A (2017). Consensus on the Asthma?COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Arch Bronconeumol., 53(8):443?449
  10. Shen LL, Liu YN, Shen HJ, Wen C, Jia YL, Dong XW, et al (2014). Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD. IntImmunopharmacol., 18(2):358-364.
  11. Singh D, Papi A, Corradi M, Pavli?ov? I, Montagna I, Francisco C, et al (2016). Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet., 388: 963?973
  12. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med.; 359(15):1543-1554
  13. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van M?lken MP, Beeh KM; POET-COPD Investigators (2011). Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. N Engl J Med., 364(12):1093-1103.

Agrawal G, Mahashur A. A. and Korukonda K. (2020); A POST-APPROVAL, OBSERVATIONAL STUDY TO ASSESS CLINICAL IMPACT OF GLYCOPYRRONIUM IN HIGH RISK COPD WITH FREQUENT EXACERBATIONS: POST HOC ANALYSES, Int. J. of Adv. Res., 8 (03), 667-673, ISSN 2320-5407. DOI URL: https://dx.doi.org/10.21474/IJAR01/10677

Dr. Gyanendra Agrawal
Sr. Consultant Pulmonologist, Jaypee Hospitals, Sector 128, Noida, India

DOI:

Article DOI: 10.21474/IJAR01/10677      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10677

Download Full Paper

Download PDF No. of Downloads: 13 | No. of Views: 51